Laredo Petroleum, Inc. (NYSE:LPI) notched a -4.47% intraday decline moving at $9.84. When the opening bell rang, the price was $10.19. The number of shares that were traded during the day was 2.17 million, which corresponds to its 3-month volume average of 3.22 million shares a day.Laredo Petroleum, Inc. (LPI) Analyst Opinion
Laredo Petroleum, Inc. has a consensus outperform rating from 22 Wall Street analysts, and the number of shares currently sold short amount to at least 15.9% of shares outstanding. The stock sank -10.55% last month and is down -30.41 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover LPI having a buy-equivalent rating. Analysts have placed a $14.17 price target on Laredo Petroleum, Inc., suggesting a 44% gain from recent close. It’s currently trading about -36.72% below its 52-week high.Laredo Petroleum, Inc. Earnings Surprise
Laredo Petroleum, Inc. (LPI) failed to surprise the stock market in its last reported earnings when it earned $0.13 a piece versus the consensus-estimated $0.14. Its revenue totaled $171.42 million down -8.33% from the previous quarter.
This stock (LPI) is ahead of its 52-week low with 3.04%. Its last month’s stock price volatility remained 4.79% which for the week stands at 3.72%. The share price has moved backward from its 20 days moving average, trading at a distance of -4.89% and stays -13.55% away from its 50 days moving average. Over the last five days, shares have faced -3.24% losses and now is down -19.28% since hitting its 200-day moving average of $11.65. Laredo Petroleum, Inc. (LPI) has made its way to a 12-month decline of -32.37%.
Turning to Calithera Biosciences, Inc. (NASDAQ:CALA), its shares were trading at $9.55 a retreat of $-0.45, on the trading floor. The stock, after opening at $10, touched a high of $10.05 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Calithera Biosciences, Inc. has 3 buy ratings, 1 holds and 0 sells even after the stock tumbled -52.37% from its high of $20.05 to a $329.86 million market value through last close.Calithera Biosciences, Inc. (CALA) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.6 to 1.6 during a month. Analysts set a 12-month price target of $18.25 a share. The target implies a 91.1% spike from where the shares are currently trading. Also, the current price highlights a discount of 130.37% to analysts’ high consensus price target.Calithera Biosciences, Inc. (NASDAQ:CALA) Intraday Trading
The counter witnessed a trading volume of 0.57 million shares versus an average volume of 0.66 million shares during last trading session. Its last month’s stock price volatility remained 6.71% which for the week approaches 10.08%. The lowest price the stock reached in the last trading day was $9.3 and compares with the $2.90 52-week low. The stock recovered 229.31% since its low point and has performed 193.85% year-to-date.